|Slideshows|October 2, 2020

Best Practices for Motivational Pharmacotherapy Sessions

Author(s)Roberto Lewis-Fernández, MD, Angela A. Coombs, MD

These techniques may help promote self-efficacy and elicit patients’ commitment to resolve ambivalence about treatment.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psychiatric Pharmacogenomics: An Overview

ByAbby Ao, DO,James A. Bourgeois, OD, MD,John J. Miller, MD

June 23rd 2026

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

ByJessica Walters

June 23rd 2026

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

ByJessica Walters

June 22nd 2026

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

ByLeah Kuntz

June 22nd 2026

Podcast: The Challenge of Medication Adherence With Martha Sajatovic, MD

ByJoseph F. Goldberg, MD,Martha Sajatovic, MD

June 19th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Best Practices for Motivational Pharmacotherapy Sessions

Related Content

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Podcast: The Challenge of Medication Adherence With Martha Sajatovic, MD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Evaluating Transdermal Asenapine in Schizophrenia